PubMed:24490627 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":103},"obj":"Sentence"},{"id":"T2","span":{"begin":104,"end":117},"obj":"Sentence"},{"id":"T3","span":{"begin":118,"end":224},"obj":"Sentence"},{"id":"T4","span":{"begin":225,"end":404},"obj":"Sentence"},{"id":"T5","span":{"begin":405,"end":644},"obj":"Sentence"},{"id":"T6","span":{"begin":645,"end":659},"obj":"Sentence"},{"id":"T7","span":{"begin":660,"end":852},"obj":"Sentence"},{"id":"T8","span":{"begin":853,"end":1059},"obj":"Sentence"},{"id":"T9","span":{"begin":1060,"end":1075},"obj":"Sentence"},{"id":"T10","span":{"begin":1076,"end":1273},"obj":"Sentence"},{"id":"T11","span":{"begin":1274,"end":1380},"obj":"Sentence"},{"id":"T12","span":{"begin":1381,"end":1563},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":103},"obj":"Sentence"},{"id":"T2","span":{"begin":104,"end":117},"obj":"Sentence"},{"id":"T3","span":{"begin":118,"end":224},"obj":"Sentence"},{"id":"T4","span":{"begin":225,"end":404},"obj":"Sentence"},{"id":"T5","span":{"begin":405,"end":644},"obj":"Sentence"},{"id":"T6","span":{"begin":645,"end":659},"obj":"Sentence"},{"id":"T7","span":{"begin":660,"end":852},"obj":"Sentence"},{"id":"T8","span":{"begin":853,"end":1059},"obj":"Sentence"},{"id":"T9","span":{"begin":1060,"end":1075},"obj":"Sentence"},{"id":"T10","span":{"begin":1076,"end":1273},"obj":"Sentence"},{"id":"T11","span":{"begin":1274,"end":1380},"obj":"Sentence"},{"id":"T12","span":{"begin":1381,"end":1563},"obj":"Sentence"}],"text":"Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?\nINTRODUCTION: Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years.\nAREAS COVERED: Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease. This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development.\nEXPERT OPINION: Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies. Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development. A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":118,"end":146},"obj":"HP_0002725"},{"id":"T2","span":{"begin":166,"end":184},"obj":"HP_0002960"},{"id":"T3","span":{"begin":166,"end":176},"obj":"HP_0002960"}],"text":"Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?\nINTRODUCTION: Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years.\nAREAS COVERED: Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease. This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development.\nEXPERT OPINION: Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies. Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development. A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population."}

{"project":"Allie","denotations":[{"id":"SS1_24490627_2_0","span":{"begin":118,"end":146},"obj":"expanded"},{"id":"SS2_24490627_2_0","span":{"begin":148,"end":151},"obj":"abbr"}],"relations":[{"id":"AE1_24490627_2_0","pred":"abbreviatedTo","subj":"SS1_24490627_2_0","obj":"SS2_24490627_2_0"}],"text":"Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?\nINTRODUCTION: Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years.\nAREAS COVERED: Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease. This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development.\nEXPERT OPINION: Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies. Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development. A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population."}